Xponance Inc. raised its position in shares of DexCom, Inc. (NASDAQ:DXCM – Get Rating) by 1.5% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 85,060 shares of the medical device company’s stock after purchasing an additional 1,245 shares during the quarter. Xponance Inc.’s holdings in DexCom were worth $9,882,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in the company. Centaurus Financial Inc. grew its stake in DexCom by 5.5% during the 1st quarter. Centaurus Financial Inc. now owns 1,236 shares of the medical device company’s stock valued at $632,000 after purchasing an additional 64 shares during the last quarter. First Horizon Advisors Inc. lifted its holdings in shares of DexCom by 9.8% in the 4th quarter. First Horizon Advisors Inc. now owns 960 shares of the medical device company’s stock valued at $109,000 after buying an additional 86 shares during the period. Fulton Bank N.A. lifted its holdings in shares of DexCom by 3.7% in the 4th quarter. Fulton Bank N.A. now owns 2,674 shares of the medical device company’s stock valued at $303,000 after buying an additional 95 shares during the period. Ascent Group LLC lifted its holdings in shares of DexCom by 2.1% in the 3rd quarter. Ascent Group LLC now owns 4,778 shares of the medical device company’s stock valued at $577,000 after buying an additional 98 shares during the period. Finally, Jaffetilchin Investment Partners LLC lifted its holdings in shares of DexCom by 7.7% in the 1st quarter. Jaffetilchin Investment Partners LLC now owns 1,412 shares of the medical device company’s stock valued at $440,000 after buying an additional 101 shares during the period. Hedge funds and other institutional investors own 93.97% of the company’s stock.
Analyst Upgrades and Downgrades
Several brokerages have recently issued reports on DXCM. Morgan Stanley began coverage on DexCom in a report on Tuesday, May 30th. They issued an “equal weight” rating and a $131.00 price objective for the company. StockNews.com started coverage on DexCom in a report on Thursday, May 18th. They issued a “buy” rating for the company. Raymond James increased their price target on DexCom from $138.00 to $140.00 in a research report on Friday, April 28th. TheStreet downgraded DexCom from a “b-” rating to a “c+” rating in a research note on Thursday, May 25th. Finally, Barclays lifted their price target on shares of DexCom from $110.00 to $115.00 in a research note on Monday, May 1st. Two equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and an average target price of $127.81.
DexCom Trading Down 0.9 %
Shares of DexCom stock opened at $123.50 on Wednesday. The stock has a market cap of $47.87 billion, a P/E ratio of 176.43, a P/E/G ratio of 2.89 and a beta of 1.15. The stock’s 50 day simple moving average is $121.86 and its 200-day simple moving average is $115.92. DexCom, Inc. has a 1-year low of $72.41 and a 1-year high of $134.14. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.02 and a quick ratio of 1.82.
DexCom (NASDAQ:DXCM – Get Rating) last issued its earnings results on Thursday, April 27th. The medical device company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.02. The business had revenue of $7.45 billion for the quarter, compared to analysts’ expectations of $720.52 million. DexCom had a return on equity of 18.29% and a net margin of 9.68%. The business’s revenue for the quarter was up 1085.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.08 EPS. Analysts predict that DexCom, Inc. will post 1.07 EPS for the current fiscal year.
Insider Transactions at DexCom
In other news, EVP Sadie Stern sold 393 shares of the business’s stock in a transaction that occurred on Monday, April 10th. The stock was sold at an average price of $112.35, for a total transaction of $44,153.55. Following the transaction, the executive vice president now directly owns 83,252 shares in the company, valued at approximately $9,353,362.20. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, EVP Sadie Stern sold 393 shares of DexCom stock in a transaction that occurred on Monday, April 10th. The shares were sold at an average price of $112.35, for a total transaction of $44,153.55. Following the sale, the executive vice president now owns 83,252 shares of the company’s stock, valued at approximately $9,353,362.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Steven Robert Pacelli sold 412 shares of DexCom stock in a transaction that occurred on Monday, April 24th. The shares were sold at an average price of $124.68, for a total transaction of $51,368.16. Following the sale, the director now directly owns 137,717 shares in the company, valued at approximately $17,170,555.56. The disclosure for this sale can be found here. Insiders have sold a total of 71,937 shares of company stock worth $8,707,980 in the last ninety days. Insiders own 0.41% of the company’s stock.
DexCom Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices for specific and permitted use cases, including non-medical device applications, medical device data analysis, integrated continuous glucose monitoring systems (iCGM) secondary display alarms, active patient monitoring, and treatment decisions; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.